Skip to Content

Join the 'High Cholesterol - Familial Heterozygous' group to help and get support from people like you.

High Cholesterol - Familial Heterozygous News

Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous

FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor

Posted 1 Aug 2016 by Drugs.com

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg of Repatha in a single dose. Repatha is a human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9), which inhibits the body's natural system for eliminating "bad" cholesterol (low-density lipoprotein cholesterol or LDL-C) from the blood.1 Repatha is the first and only PCSK9 inhibitor to offer a monthly single-dose delivery option. Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge) "The Pushtronex system exemplifies Amgen's continued innovation and c ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Repatha, Evolocumab

Inherited Cholesterol Disorder Significantly Boosts Heart Risks

Posted 30 Jun 2016 by Drugs.com

THURSDAY, June 30, 2016 – People who inherit a genetic disorder that causes high levels of "bad" LDL cholesterol have an increased risk for heart disease and hardened arteries, a new study finds. The condition is called heterozygous familial hypercholesterolemia. It's believed to affect about 1.5 million people in the United States, the researchers said. The genes linked to this condition prevent the liver from removing LDL (low-density lipoprotein) cholesterol from the blood. This allows the bad cholesterol to build up. Doctors suspect this familial condition when LDL levels are above 190 milligrams per deciliter (mg/dL), the study authors explained. The researchers reviewed data from six groups of people involved in previous studies. Compared to people with average LDL cholesterol levels (less than 130 mg/dL), those with familial hypercholesterolemia had a five times higher risk for ... Read more

Related support groups: Heart Disease, High Cholesterol, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease, Cardiovascular Risk Reduction

Genetic High-Cholesterol Condition More Common Than Thought

Posted 14 Mar 2016 by Drugs.com

MONDAY, March 14, 2016 – Twice as many people as previously thought are genetically predisposed to develop dangerously high cholesterol levels, new research suggests. Familial hypercholesterolemia, as this condition is called, significantly ups the risk for an early heart attack. The study found it affects about one in every 250 American men and women, rather than one in 500. The new numbers don't reflect a problem on the rise, however, said study author Dr. Sarah de Ferranti, an assistant professor of pediatrics at Harvard Medical School. Instead, the condition was previously "under-recognized," she explained. For those who have this potentially deadly condition, "it is extremely important to get early, consistent preventive care," de Ferranti said. "The key is for you and your clinician to understand and distinguish between mild to moderately high cholesterol that comes on in middle ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Zetia, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Pravachol, High Cholesterol - Familial Homozygous, Livalo, Red Yeast Rice, Ezetimibe, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol

Statins May Reduce Heart Risks Linked to Sleep Apnea: Study

Posted 6 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – A new discovery about the way sleep apnea may raise the risk of heart disease also suggests that taking cholesterol-lowering statin drugs might reduce that risk, according to a new study. Sleep apnea is a common disorder that involves irregular breathing while asleep, with oxygen intake dropping frequently for brief periods. The condition can triple a person's risk of stroke, high blood pressure and other heart problems, said study author Dr. Sanja Jelic, an associate professor of medicine at Columbia University Medical Center in New York City. Statins such as Crestor (rosuvastatin) and Lipitor (atorvastatin) are already taken by millions of Americans to reduce their risk of heart disease. "If the beneficial effects of statins on blood vessel health in patients with obstructive sleep apnea is confirmed in larger clinical trials, obstructive sleep apnea may ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Sleep Apnea, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Cardiovascular Risk Reduction, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol

U.S. Task Force Backs Statins for Those 40 to 75 at Heightened Heart Risk

Posted 22 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Cholesterol-lowering statin drugs should be used to prevent a first heart attack or stroke in certain at-risk patients, according to a draft recommendation released Monday by the nation's leading experts in preventive medicine. The U.S. Preventive Services Task Force said statins can provide maximum preventive benefits for adults 40 to 75 years old who have an existing risk factor for heart disease and at least a 10 percent or greater risk of a heart attack or stroke sometime within the next 10 years. The independent panel added that people with a 10-year risk of heart attack and stroke between 7.5 percent and 10 percent might also benefit from statins, and should discuss the matter with their doctor. "Cardiovascular disease is a leading cause of death, and people with no signs or symptoms or past history of cardiovascular disease can still be at risk," said ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Pravachol, High Cholesterol - Familial Homozygous, Livalo, Red Yeast Rice, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol, Lescol XL, Mevacor

U.S. Task Force Stays Neutral on Cholesterol Screening for Kids

Posted 22 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – There's not enough evidence to recommend screening all children and teens for high cholesterol, experts say. It's not clear if such screening up to age 20 reduces the risk of cardiovascular disease in adulthood, the U.S. Preventive Services Task Force said in a draft recommendation released Monday. This is unchanged from a 2007 recommendation. "There is currently not enough research to determine whether screening all average-risk children and adolescents without symptoms leads to better cardiovascular health in adulthood," task force vice chair Dr. David Grossman said in a news release from the task force. "In addition, the potential harms of long-term use of cholesterol-lowering medication by children and adolescents are not yet understood," Grossman added. The task force is an independent, volunteer panel of national experts in prevention and evidence-based ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Pravachol, High Cholesterol - Familial Homozygous, Livalo, Red Yeast Rice, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol, Lescol XL, Mevacor

One in Five U.S. Kids Over Age 5 Has Unhealthy Cholesterol: CDC

Posted 10 Dec 2015 by Drugs.com

THURSDAY, Dec. 10, 2015 – Twenty-one percent of American children and teens have some form of "abnormal" blood cholesterol reading that leaves them at heightened risk for heart disease and stroke as they reach adulthood. That's the conclusion of a review of 2011-2014 federal health data compiled by researchers at the U.S. Centers for Disease Control and Prevention. Overall, slightly more than 13 percent of kids had unhealthily low levels of HDL ("good") cholesterol – the kind that actually might help clear out arteries. The CDC says just over 8 percent had too-high levels of other forms of cholesterol that are bad for arteries, and more than 7 percent had unhealthily high levels of "total" cholesterol. Obesity helped drive these trends, the CDC said. For example, more than 43 percent of children who were obese had some form of abnormal cholesterol reading, compared to less than 14 ... Read more

Related support groups: Obesity, High Cholesterol, Lipitor, Weight Loss, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Pravachol, Livalo, High Cholesterol - Familial Homozygous, Ischemic Stroke - Prophylaxis, Red Yeast Rice, Cardiovascular Risk Reduction, Thromboembolic Stroke Prophylaxis

Study Sees Link Between High Cholesterol and Tendon Trouble

Posted 16 Oct 2015 by Drugs.com

FRIDAY, Oct. 16, 2015 – High cholesterol levels may increase your risk of tendon problems and pain, a new study suggests. Tendons are the tough fibers connecting the body's muscles and bones. The researchers suspect cholesterol buildup in immune cells can lead to chronic low-level inflammation, prompting tendon abnormalities and pain. They analyzed 17 studies published between 1973 and 2014 that included more than 2,600 people. Compared to those with normal tendon structure, people with abnormal tendon structure had higher total cholesterol. They also had higher levels of "bad" low-density cholesterol, lower levels of "good" high-density cholesterol, and higher levels of blood fats called triglycerides, the researchers found. People with high cholesterol levels were also much more likely to have tendon injuries, higher levels of musculoskeletal-related pain in their arms, and thicker ... Read more

Related support groups: High Cholesterol, Tendonitis, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia

FDA Approves Repatha for High Cholesterol

Posted 31 Aug 2015 by Drugs.com

FRIDAY, Aug. 28, 2015 – Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration, the second non-statin drug in its class approved to treat high cholesterol. The injected drug, among a new class called PCSK9 inhibitors, is sanctioned for people who are unable to reduce levels of the so-called LDL "bad" cholesterol with statin therapy and exercise, the agency said in a news release. Low-density lipoprotein, commonly known as LDL, builds up in the blood from natural and food sources, and is a leading cause of heart disease. About one in four deaths in the United States is linked to heart disease, making it the top cause of death among men and women. The condition kills about 610,000 people in the United States annually, the FDA said. Repatha is an antibody that targets the PCSK9 protein, which inhibits the liver's ability to remove LDL from the blood. Its most ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA Approves Repatha - Second Drug in New Class of Cholesterol-Lowering Medications

Posted 31 Aug 2015 by Drugs.com

THURSDAY, Aug. 27, 2015 – The U.S. Food and Drug Administration on Thursday approved a second drug that's part of a potent new class of medications that sharply cut levels of "bad" LDL cholesterol. Repatha (evolocumab), an injectable drug, works by blocking a protein that interferes with the liver's ability to remove LDL cholesterol from the blood. In July, the FDA approved Praluent (alirocumab), another injectable drug in the same class of medications as Repatha. Both drugs are called PCSK9 inhibitors, which don't seem to cause the muscle problems that cholesterol-lowering statin drugs sometimes can. "Repatha provides another treatment option in this new class of drugs for patients with familial hypercholesterolemia or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough with statins," said Dr. John Jenkins, director of the FDA's Office of New ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol

Posted 31 Aug 2015 by Drugs.com

August 27, 2015 – The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Familial hypercholesterolemia (encompassing both HeFH and HoFH) is an inherited condition that causes high levels of LDL cholesterol. A high level of LDL cholesterol in the blood is linked to cardiovascular or heart disease. Heart ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA OKs Praluent - First of New Class of Cholesterol Drugs

Posted 27 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – The U.S. Food and Drug Administration on Friday approved Praluent, the first of a powerful new class of injected, cholesterol-lowering drugs that experts believe could change cardiovascular care. Praluent (alirocumab) sharply cuts levels of LDL ("bad") cholesterol, and is one of a group of newly developed drugs called PCSK9 inhibitors, the FDA explained in a news release. The drug is only approved for patients with heart disease and a history of heart attack or stroke "who require additional lowering of LDL cholesterol" in addition to taking a statin drug and adopting a healthy diet, the agency said. It is also for use by patients with a condition called heterozygous familial hypercholesterolemia (HeFH), an inherited illness that causes people to have high levels of LDL in the blood. "Praluent provides another treatment option for patients with HeFH or with ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Praluent Approved to Treat High Cholesterol

Posted 27 Jul 2015 by Drugs.com

MONDAY, July 27, 2015 – Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration to treat people with inherited high cholesterol (heterozygous familial hypercholesterolemia) or people at risk of heart attack or stroke from high cholesterol derived from foods or produced by the liver. The drug is sanctioned for people who do not benefit enough from improved diet and the use of cholesterol-lowering statins. Low-density lipoprotein (LDL, the so-called "bad cholesterol") is linked to cardiovascular disease. Heart disease is the leading cause of death among American men and women, killing some 610,000 people every year, the FDA said in a news release. Praluent is the first-approved drug in a new class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The drug is an antibody that inhibits the PCSK9 protein, which allows ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol

Posted 27 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. HeFH is an inherited condition that causes high levels of low-density lipoprotein (LDL) cholesterol. A high level of LDL cholesterol (known as “bad” cholesterol) in the blood is linked to cardiovascular disease. Heart disease is the number one cause of death for Americans, both men and women. According to the Centers for Disease Con ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Wider Use of Statin Drugs Could Save Thousands More Lives: Report

Posted 14 Jul 2015 by Drugs.com

TUESDAY, July 14, 2015 – New expert guidelines from two major cardiologists' groups may boost doctors' ability to spot patients who should take cholesterol-lowering statin drugs, researchers said. The updated guidelines were released in 2013 by the American College of Cardiology and the American Heart Association. Now, a new report finds they are more accurate and efficient than earlier guidelines in identifying adults at high risk for heart trouble who could gain from statins. All of that should add up to lives saved, the researchers said. "Extrapolating our results to the approximately 10 million U.S. adults who would be newly eligible for statin therapy under the new guidelines, we estimate that between 41,000 and 63,000 cardiovascular events – heart attacks, strokes or deaths from cardiovascular disease – would be prevented over a 10-year period," lead researcher Dr. Udo Hoffman, ... Read more

Related support groups: Heart Disease, High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Coronary Artery Disease (CAD), Pravachol, Livalo, High Cholesterol - Familial Homozygous, Red Yeast Rice, Cardiovascular Risk Reduction, Ischemic Heart Disease, Lescol

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol

Related Drug Support Groups

Lipitor, simvastatin, Crestor, atorvastatin, pravastatin, Zocor, lovastatin, Zetia, Vytorin, view more... rosuvastatin, Pravachol, Repatha, ezetimibe, Praluent, Lescol, Lescol XL, Mevacor, Advicor, fluvastatin, alirocumab, Altoprev, lovastatin / niacin, Repatha Pushtronex, Juvisync, simvastatin / sitagliptin, ezetimibe / simvastatin, evolocumab, Altocor